{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-206655","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2024-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.464320+00:00","generated_at":"2026-05-31T07:41:08.879067+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Eliem Therapeutics appoints Brett Kaplan as COO with equity grants","bullets":["Brett Kaplan, M.D., appointed Chief Operating Officer effective August 26, 2024.","Base salary of $500,000/year; eligible for annual bonus up to 45% of base salary.","Granted option to purchase 465,000 shares and 77,500 RSUs under 2021 Equity Incentive Plan.","Option vests 25% at one year then monthly over 3 years; RSUs vest 25% annually over 4 years.","Severance: 9 months salary (non-CIC) or 12 months plus target bonus (CIC), plus COBRA and equity acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-206655","json":"https://secwatch.observer/filing/0001193125-24-206655.json","markdown":"https://secwatch.observer/filing/0001193125-24-206655.md","text":"https://secwatch.observer/filing/0001193125-24-206655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312524206655/0001193125-24-206655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312524206655/d866047d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:41:08.879067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"327433d009","claim":"Brett Kaplan, M.D. was appointed as Chief Operating Officer at Climb Bio, Inc..","evidence_excerpt":"On August 26, 2024, Eliem Therapeutics, Inc. (the “Company”) announced that its board of directors (the “Board”) had appointed Brett Kaplan, M.D., as Chief Operating Officer of the Company, effective August 26, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312524206655/0001193125-24-206655-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}